Clinical trials: Hurthle Cell Thyroid Cancer, active
Hurthle Cell Thyroid Cancer, Tall Cell Variant Thyroid Cancer
Studies on Tumors of the Thyroid
Participants in this study will be patients diagnosed with or suspected to have a thyroid nodule or thyroid cancer. The main purpose of this study is to further understand the methods for the diagnosis and treatment of thyroid…
- Conditions
- Hurthle Cell Thyroid Cancer, Tall Cell Variant Thyroid Cancer, Follicular Thyroid Cancer, Thyroid Cancer
- Trial name
- NCT00001160
- Testing
- 68-Gallium Dotatate
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Thyroid Cancer, Thyroid Neoplasms
IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
IoN is a phase II/III trial that will look to ascertain whether or not radio-iodine ablation is necessary for low risk differentiated thyroid cancer patients.
- Trial name
- IoN (NCT01398085)
- Testing
- I131 1.1 GBq, No Radioactive iodine (No-RAI) ablation
- Where
- 36 sites in United Kingdom
- Volunteers
- 504 people
- Sponsor
- University College, London
Refractory Hurthle Cell Thyroid Cancer
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
This randomized phase II trial studies the effects, good and bad, of using everolimus along with sorafenib tosylate versus sorafenib tosylate alone in treating patients with advanced radioactive iodine refractory thyroid cancer.
- Trial name
- NCT02143726
- Testing
- sorafenib, everolimus
- Where
- 21 sites in United States
- Volunteers
- 35 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Thyroid Cancer, Thyroid Cancer, Follicular
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
The purpose of this study is to find out whether a drug called PDR001, combined with either trametinib or dabrafenib, is a safe and effective treatment for thyroid cancer.
- Conditions
- Thyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer, Follicular Thyroid Cancer
- Trial name
- NCT04544111
- Testing
- Trametinib, Dabrafenib, PDR001
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Thyroid Cancer
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Background: Oncocytic (Hurthle cell) thyroid cancer (HTC) is a rare disease with few treatment options. Researchers are developing a radioactive drug that targets a protein that appears in high numbers on HTC cancer cells.
- Trial name
- NCT06991738
- Testing
- 68Ga-DOTA-TATE PET Scan, Amino acid infusions, 177Lu-DOTA-EB-TATE
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)